International Biopharmaceutical Industry covers the latest research, innovation, and regulatory changes, with each quarterly print issue distributed to 21,400 readers.
Biologic formulations for subcutaneous delivery allow patients to self-administer their treatments, reducing the need for hospital visits. As a result, intravenous formulations are now being updated for subcutaneous injection when possible to leverage these advantages.
In this article, we explore the challenges faced by manufacturers and device engineers as they adapt drug delivery devices to new biologic formulations, as well as the main strategies and advances in the industry to address these issues.